CIA
AUPH icon

Concurrent Investment Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Concurrent Investment Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$409K Sell
24,082
-7,442
-24% -$119K ﹤0.01% 1518
2026
Q1 		$467K Buy
31,524
+1,254
+4% +$18.3K 0.01% 1249
2025
Q4 		$483K Buy
30,270
+2,200
+8% +$31.2K 0.01% 1160
2025
Q3 		$310K Hold
28,070
– – 0.01% 1137
2025
Q2 		$238K Buy
+28,070
New +$225K ﹤0.01% 1184

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Concurrent Investment Advisors's AUPH Position: Q2 2026 in Review

Concurrent Investment Advisors reduced its Aurinia Pharmaceuticals (AUPH) stake by 24% in Q2 2026, selling an estimated $119K and leaving 24,082 shares worth $409K. The position accounts for ﹤0.01% of the portfolio, ranked #1518.

Concurrent Investment Advisors first reported a position in AUPH in Q2 2025 and has held it in 5 quarters since. The position peaked at $483K in Q4 2025. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Concurrent Investment Advisors held 24,082 shares of Aurinia Pharmaceuticals worth $409K as of Q2 2026.
  • Concurrent Investment Advisors sold 7,442 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $119K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #1518 holding.
  • Concurrent Investment Advisors first reported a position in Aurinia Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Concurrent Investment Advisors's Aurinia Pharmaceuticals position peaked at $483K in Q4 2025.
  • 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.